Key Drivers
- Cash Rich
- Heavy Burn
- No Revenue
AIAI Summary
GHRS has evolved from a speculative psychedelic story into a more credible late-stage biotech setup after its Phase 2b/JAMA publication and IND-opening work, but with all value still tied to GH001 and no revenue, the stock remains a binary Phase 3 execution bet where strong cash buys time, not safety.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Rich
- •Heavy Burn
- •No Revenue
GHRS has an exceptionally strong cash-backed balance sheet, but with no revenue, persistent losses, and ongoing cash burn, the investment case hinges on preserving capital and converting pipeline value into future sales.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Range pause
- •Support hold
GHRS remains technically constructive after rising from $18.34 to $21.39 over the last month with higher lows, but it is consolidating below $22.44 and needs to hold above about $21.00 to avoid a deeper pullback.
Sharp rebound from around $20.53–$20.71, followed by a pullback from $22.44 to $21.39
Sentiment & News
Key News Insights:
- •Capital Raise
- •Trial Progress
- •Wider Loss
GH Research raised $117.5M to bolster liquidity, advanced multiple Phase 2b programs, and drew a mixed investor response after a wider-than-expected Q1 loss.
The news is modestly positive for the stock's long-term clinical outlook, but near-term sentiment may stay pressured by earnings weakness
Similar Companies in Healthcare
Other companies in the same sector with AI ratings